The EORTC has been very active assembling the pan-European SPECTAcolor network, and ICO -VHIO has proven to be very valuable partners in this endeavor to quickly find a cure for patients with colorectal cancer. In Spain, the EORTC has been closely working with the Catalan Institute of Oncology (ICO) and Vall d’Hebron Institute of [...]

Over 500 patients in and availability of high quality biological materials SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. It has been successfully implemented across 21 clinical centers located in nine countries in Europe, has now recruited over 500 patients since its launch in September 2013, and the observed [...]

The EORTC is pleased to announce the successful implementation of SPECTAcolor, ‘Screening Patients for Efficient Clinical Trial Access’ - the first Pan European collaborative molecular screening platform for colorectal cancer patients. SPECTAcolor proves the logistical feasibility of the infrastructure that was built to run next generation trials in a multinational setting.

SPECTAcolor, the EORTC’s premier Screening Platform for Efficient Clinical Trial Access for patients with colorectal cancer, enrolled its 100th patient in February 2014.

Extensive screening is required when clinical trials in colorectal cancer (CRC) are conducted. CRCs have different molecular profiles, and it is of interest to be able to design treatments for these molecular subtypes. The SPECTAcolor screening platform for patients with advanced colorectal cancer aims to increase the chance for these patients to access clinical trials with new molecularly defined approaches in the network of the EORTC Gastrointestinal Cancer Group.